---
document_datetime: 2023-09-21 18:51:41
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/scientific-conclusion/strensiq-epar-scientific-conclusion_en.pdf
document_name: strensiq-epar-scientific-conclusion_en.pdf
version: success
processing_time: 0.488245
conversion_datetime: 2025-12-22 13:46:43.634961
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Annex IV

Conclusions on the granting of the marketing authorisation under exceptional circumstances presented by the European Medicines Agency

<div style=\"page-break-after: always\"></div>

## Conclusions presented by the European Medicines Agency on:

## Â· Marketing authorisation under exceptional circumstances

The CHMP having considered the application is of the opinion that the risk-benefit balance is favourable to recommend the granting of the marketing authorisation under exceptional circumstances as further explained in the European Public Assessment Report.